Literature DB >> 36104655

Difficult-to-Treat Rheumatoid Arthritis in Older Adults: Implications of Ageing for Managing Patients.

Marta Novella-Navarro1, Alejandro Balsa2.   

Abstract

Difficult-to-treat rheumatoid arthritis is a heterogeneous term in which patients may present with difficulties in their management for different reasons. This can ultimately lead to patients being exposed to multiple treatments because of inefficacy (resulting from mechanisms intrinsic to rheumatoid arthritis or from non-inflammatory causes such as chronic pain syndrome or structural damage, among others), toxicity or adverse effects that may be linked to comorbidities. One particular group in which such characteristics may be more patent is older patients. Increasing life expectancy, an ageing population and the late onset of rheumatoid arthritis have led to an increased interest in the particularities of treating older patients. This may pose a challenge for physicians, as ageing has implications for optimal patient treatment owing to the potential presence of comorbidities, the risk of adverse events and perceptions of disease status by both physicians and patients. All of these factors may have implications for classifying and managing patients aged > 65 years as difficult-to-treat rheumatoid arthritis, as these patients could be misclassified. This can occur when a significant proportion may still exhibit signs of active disease but not necessarily be difficult to treat because the treatment criterion has not been fulfilled. Alternatively, patients may be exposed to multiple biologic/targeted disease-modifying antirheumatic drugs because of contraindications and/or comorbid conditions. Treatment-to-target strategies and an adequate assessment of inflammatory rheumatoid arthritis activity in older patients should be undertaken, taking special care with associated comorbidities, polypharmacy and risk profiles. Such an approach can help to ensure appropriate treatment for older adults and avoid the misclassification of difficult-to-treat patients.
© 2022. The Author(s).

Entities:  

Year:  2022        PMID: 36104655     DOI: 10.1007/s40266-022-00976-5

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   4.271


  69 in total

1.  Characteristics of difficult-to-treat rheumatoid arthritis: results of an international survey.

Authors:  Nadia M T Roodenrijs; Maria J H de Hair; Marlies C van der Goes; Johannes W G Jacobs; Paco M J Welsing; Désirée van der Heijde; Daniel Aletaha; Maxime Dougados; Kimme L Hyrich; Iain B McInnes; Ulf Mueller-Ladner; Ladislav Senolt; Zoltan Szekanecz; Jacob M van Laar; György Nagy
Journal:  Ann Rheum Dis       Date:  2018-09-07       Impact factor: 19.103

Review 2.  Rheumatoid arthritis.

Authors:  Josef S Smolen; Daniel Aletaha; Iain B McInnes
Journal:  Lancet       Date:  2016-05-03       Impact factor: 79.321

Review 3.  Defining refractory rheumatoid arthritis.

Authors:  Maya H Buch
Journal:  Ann Rheum Dis       Date:  2018-03-27       Impact factor: 19.103

4.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.

Authors:  Josef S Smolen; Robert B M Landewé; Johannes W J Bijlsma; Gerd R Burmester; Maxime Dougados; Andreas Kerschbaumer; Iain B McInnes; Alexandre Sepriano; Ronald F van Vollenhoven; Maarten de Wit; Daniel Aletaha; Martin Aringer; John Askling; Alejandro Balsa; Maarten Boers; Alfons A den Broeder; Maya H Buch; Frank Buttgereit; Roberto Caporali; Mario Humberto Cardiel; Diederik De Cock; Catalin Codreanu; Maurizio Cutolo; Christopher John Edwards; Yvonne van Eijk-Hustings; Paul Emery; Axel Finckh; Laure Gossec; Jacques-Eric Gottenberg; Merete Lund Hetland; Tom W J Huizinga; Marios Koloumas; Zhanguo Li; Xavier Mariette; Ulf Müller-Ladner; Eduardo F Mysler; Jose A P da Silva; Gyula Poór; Janet E Pope; Andrea Rubbert-Roth; Adeline Ruyssen-Witrand; Kenneth G Saag; Anja Strangfeld; Tsutomu Takeuchi; Marieke Voshaar; René Westhovens; Désirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2020-01-22       Impact factor: 19.103

Review 5.  2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.

Authors:  Jasvinder A Singh; Kenneth G Saag; S Louis Bridges; Elie A Akl; Raveendhara R Bannuru; Matthew C Sullivan; Elizaveta Vaysbrot; Christine McNaughton; Mikala Osani; Robert H Shmerling; Jeffrey R Curtis; Daniel E Furst; Deborah Parks; Arthur Kavanaugh; James O'Dell; Charles King; Amye Leong; Eric L Matteson; John T Schousboe; Barbara Drevlow; Seth Ginsberg; James Grober; E William St Clair; Elizabeth Tindall; Amy S Miller; Timothy McAlindon
Journal:  Arthritis Rheumatol       Date:  2015-11-06       Impact factor: 10.995

6.  Difficult-to-treat rheumatoid arthritis: an area of unmet clinical need.

Authors:  Maria J H de Hair; Johannes W G Jacobs; Jan L M Schoneveld; Jacob M van Laar
Journal:  Rheumatology (Oxford)       Date:  2018-07-01       Impact factor: 7.580

Review 7.  Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force.

Authors:  Josef S Smolen; Ferdinand C Breedveld; Gerd R Burmester; Vivian Bykerk; Maxime Dougados; Paul Emery; Tore K Kvien; M Victoria Navarro-Compán; Susan Oliver; Monika Schoels; Marieke Scholte-Voshaar; Tanja Stamm; Michaela Stoffer; Tsutomu Takeuchi; Daniel Aletaha; Jose Louis Andreu; Martin Aringer; Martin Bergman; Neil Betteridge; Hans Bijlsma; Harald Burkhardt; Mario Cardiel; Bernard Combe; Patrick Durez; Joao Eurico Fonseca; Alan Gibofsky; Juan J Gomez-Reino; Winfried Graninger; Pekka Hannonen; Boulos Haraoui; Marios Kouloumas; Robert Landewe; Emilio Martin-Mola; Peter Nash; Mikkel Ostergaard; Andrew Östör; Pam Richards; Tuulikki Sokka-Isler; Carter Thorne; Athanasios G Tzioufas; Ronald van Vollenhoven; Martinus de Wit; Desirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2015-05-12       Impact factor: 19.103

8.  Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.

Authors:  Lianne Kearsley-Fleet; Rebecca Davies; Diederik De Cock; Kath D Watson; Mark Lunt; Maya H Buch; John D Isaacs; Kimme L Hyrich
Journal:  Ann Rheum Dis       Date:  2018-07-06       Impact factor: 19.103

9.  Clinical predictors of multiple failure to biological therapy in patients with rheumatoid arthritis.

Authors:  Marta Novella-Navarro; Chamaida Plasencia; Carolina Tornero; Victoria Navarro-Compán; José L Cabrera-Alarcón; Diana Peiteado-López; Laura Nuño; Irene Monjo-Henry; Karen Franco-Gómez; Alejandro Villalba; Alejandro Balsa
Journal:  Arthritis Res Ther       Date:  2020-12-09       Impact factor: 5.156

10.  EULAR definition of difficult-to-treat rheumatoid arthritis.

Authors:  Désirée van der Heijde; Jacob M van Laar; György Nagy; Nadia Mt Roodenrijs; Paco Mj Welsing; Melinda Kedves; Attila Hamar; Marlies C van der Goes; Alison Kent; Margot Bakkers; Etienne Blaas; Ladislav Senolt; Zoltan Szekanecz; Ernest Choy; Maxime Dougados; Johannes Wg Jacobs; Rinie Geenen; Hans Wj Bijlsma; Angela Zink; Daniel Aletaha; Leonard Schoneveld; Piet van Riel; Loriane Gutermann; Yeliz Prior; Elena Nikiphorou; Gianfranco Ferraccioli; Georg Schett; Kimme L Hyrich; Ulf Mueller-Ladner; Maya H Buch; Iain B McInnes
Journal:  Ann Rheum Dis       Date:  2020-10-01       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.